BAY-9835: Discovery of the First Orally Bioavailable ADAMTS7 Inhibitor-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

BAY-9835: Discovery of the First Orally Bioavailable ADAMTS7 Inhibitor

Published:2024-02-13 Issue:4 Volume:67 Page:2907-2940
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Meibom Daniel¹^ORCID,Wasnaire Pierre¹,Beyer Kristin¹,Broehl Andreas¹,Cancho-Grande Yolanda¹,Elowe Nadine²,Henninger Kerstin¹,Johannes Sarah¹,Jungmann Natalia¹,Krainz Tanja²,Lindner Niels¹,Maassen Stefanie¹,MacDonald Bryan²^ORCID,Menshykau Denis¹,Mittendorf Joachim¹,Sanchez Guzman³,Schaefer Martina⁴,Stefan Eric²,Torge Afra¹,Xing Yi²,Zubov Dmitry¹

Affiliation:

1. Bayer AG, 42113 Wuppertal, Germany

2. Broad Institute, 02142 Cambridge, United States

3. Villapharma Research, 30320 Murcia, Spain

4. Bayer AG, 13353 Berlin, Germany

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.3c02036

Reference64 articles.

1. Atherosclerosis

2. Recent Update on the Development of PCSK9 Inhibitors for Hypercholesterolemia Treatment

3. Novel Antiatherosclerotic Therapies

4. Genetics of coronary artery disease: discovery, biology and clinical translation

5. Coronary Artery Disease Genetics Enlightened by Genome-Wide Association Studies

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design, synthesis and biological evaluation of arylsulfonamides as ADAMTS7 inhibitors;RSC Medicinal Chemistry;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP